Search clinical trials for: AG-519

Total 2466 results

Agios Pharmaceuticals, Inc.

Terminated

A Safety and Tolerability Study of AG-519 in Healthy Subjects

Anemia

United Kingdom
University of Oxford

Completed

Research on Community Based ATK Test Study to Control Spread of COVID-19 in Migrant Community (CATK)

COVID-19 Pandemic

Thailand
Vedic Lifesciences Pvt. Ltd.
Enovate Biolife Pvt Ltd

Completed

A Study to Evaluate Efficacy of IP on Alertness and Mental Fatigue (ALERMEN)

Mental Fatigue

India
University of Wisconsin, Madison

Completed

Safe and Healthy Schools

COVID-19 | Sars-CoV-2 Infection

United States
Foundation for Innovative New Diagnostics, Switzerland
Botswana Harvard AIDS Institute Partnership

Completed

COVID-19 Antigen Rapid Test Evaluation in Low-Prevalence Setting (CV006)

Corona Virus Infection

Botswana
Rigshospitalet, Denmark
Testcenter Danmark, Statens Serum Institut; Copenhagen Emergency Medical Services

Completed

Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test

Covid19 | SARS-CoV-2 | Rapid Antigen Test

Denmark
Somerset NHS Foundation Trust

Unknown

Somerset and South Essex Coronavirus Antigen Testing (SOCRATES)

SARS-CoV 2 | COVID

United Kingdom
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Healthy Volunteers

United States
Molnlycke Health Care AB

Completed

Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers

Venous Leg Ulcers | Mixed Leg Ulcers

France, Germany, Netherlands, Czech Republic
Agios Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Healthy Male Participants

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Healthy Volunteers

United States
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer

Ovarian Cancer

Israel
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms

United States, Israel
University of British Columbia
Providence Health & Services; Vancouver Airport Authority; WestJet Airlines; KLM...

Completed

An Approach to Screening for COVID-19 at Vancouver Airport

Healthy | Asymptomatic Condition

Canada
bioLytical Laboratories

Completed

Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC

COVID-19 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19

United States
Joint Authority for Päijät-Häme Social and Health...

Recruiting

Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service (AGS)

Arthroplasty Complications | Dysglycemia

Finland
Agios Pharmaceuticals, Inc.

Terminated

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Lymphoma

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Healthy | Japanese | Non-Asian

United States
Ahn-Gook Pharmaceuticals Co.,Ltd
Hanyang University; Ewha Womans University; Konkuk University Medical Center; Kyunghee... and other collaborators

Completed

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup"

Bronchitis | Acute Upper Respiratory Tract Infections

Korea, Republic of
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Pfizer

Terminated

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, United Kingdom, Australia, Netherlands
Molnlycke Health Care AB

Recruiting

Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

Partial-thickness Burn

United States
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Coloplast A/S

Completed

Biatain Ag vs Biatain in the Treament of Leg Ulcers

Leg Ulcers
Brigham and Women's Hospital
Medline Industries

Completed

Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects (STSG)

Split-thickness Skin Graft Donor Sites
Karl Landsteiner University of Health Sciences
Ludwig Boltzmann Gesellschaft

Not yet recruiting

The Effectiveness of a Serious Game Targeting Interpersonal Emotion Regulation in Early Adolescents

Interpersonal Relations
The University of Texas Medical Branch, Galveston

Withdrawn

PermeaDerm® vs. Mepilex-Ag® in Promoting Healing of Partial-thickness Burn Wounds

Partial-thickness Burn

United States
University of Wisconsin, Madison

Terminated

BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)

COVID-19 | SARS-CoV2 Infection

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France
Second Affiliated Hospital of Wenzhou Medical University

Completed

Clinical Value of the MRI Combined With SCC-Ag for the Diagnosis of HSIL (CIN 2/3)

Magnetic Resonance Imaging Examination

China
Agios Pharmaceuticals, Inc.

Completed

A Phase I Study of AG-348 in Healthy Volunteers (AG-348MAD)

Healthy Volunteer

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Molnlycke Health Care AB

Completed

A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients. (MpTAg03)

Burn Injury | Skin Graft

United States
Stedical Scientific, Inc.

Recruiting

Evaluation of the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag®

Thermal Burn

United States
Celgene
Agios Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Hematologic Neoplasms

United States, France
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Minia University

Completed

Macular Vessels Density Before and After PRP in Patients With Proliferative Diabetic Retinopathy

PRP

Egypt
Servier
Servier Pharmaceuticals, LLC

Available

Vorasidenib Expanded Access Program

Pathologic Processes | Glioma | Neoplasms | Neoplasms by Histologic Type | Neoplasms, Glandular and Epithelial | Recurrence | Disease Attributes | Neoplasms, Germ Cell and Embryonal | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue
University of Florida
Hospital Santo Tomas

Withdrawn

Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama

HIV | Tuberculosis | Histoplasmosis
Molnlycke Health Care AB

Completed

Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

Wounds and Injuries

United States
Anchiano Therapeutics Israel Ltd.

Completed

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Superficial Bladder Cancer

Israel, United States
Centre Hospitalier Universitaire Vaudois
B. Braun Melsungen AG

Completed

Intra- Versus Extraplexic Catheter Placement for Continuous Interscalene Brachial Plexus Block

Shoulder Pain | Regional Anesthesia Morbidity | Shoulder Arthritis

Switzerland
Rigshospitalet, Denmark
Emergency Medical Services, Capital Region, Denmark; Technical University of... and other collaborators

Completed

Diagnostic Accuracy of Self-sampling Versus Healthcare Sampling for Coronavirus-Disease-2019 Detection. (COVID-19)

COVID-19 Pandemic

Denmark
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Celgene
Celgene Corporation

Completed

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Glioma | Solid Tumor | Angioimmunoblastic T-cell Lymphoma | Chondrosarcoma | Intrahepatic Cholangiocarcinoma

United States, France
Coloplast A/S

Recruiting

A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

Wound Heal

Germany, United States, Denmark

Search clinical trials for: AG-519

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations